Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scandinavian Real Heart AB's revenue for the
six
months ended in Dec. 2025 was €0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.
Scandinavian Real Heart AB's Revenue per Share for the
six
months ended in Dec. 2025 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Scandinavian Real Heart AB's highest 3-Year average Revenue per Share Growth Rate was 37.10% per year. The lowest was 37.10% per year. And the median was 37.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Scandinavian Real Heart AB Revenue Related Terms
Scandinavian Real Heart AB Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Scandinavian Real Heart AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scandinavian Real Heart AB Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scandinavian Real Heart AB's Revenue distribution charts can be found below:
* The bar in red indicates where Scandinavian Real Heart AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scandinavian Real Heart AB (FRA:7820) has a Revenue of €0.00 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Scandinavian Real Heart AB and its competitors.
Is Scandinavian Real Heart AB's Revenue too high?
Scandinavian Real Heart AB's current Revenue is €0.00 Mil. Overall, Scandinavian Real Heart AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Scandinavian Real Heart AB's Revenue compare to ABT and SYK?
Scandinavian Real Heart AB's Revenue of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Scandinavian Real Heart AB and its competitors. Scandinavian Real Heart AB's current Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scandinavian Real Heart AB stock overvalued right now?
Scandinavian Real Heart AB (FRA:7820) has a current Revenue of €0.00 Mil. The current Revenue is €0.00 Mil. Scandinavian Real Heart AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Scandinavian Real Heart AB (FRA:7820), the current Revenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scandinavian Real Heart AB is engaged in developing an artificial heart that mimics the shape, function, and bloodflow pattern of the human heart. The company conducts research and development in medical technology and is developing an artificial heart that mimics the function of a natural heart - a so-called total artificial heart (TAH), Realhear, TAH. It is a Swedish-patented product that saves lives and improves the quality of life.
32GF Score
Get the complete analysis for FRA:7820
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7820 has been successfully added to your 
